The abstract is read at the publisher; the summary is JClub's.
BAFF is significantly upregulated in SLE-PAH, and BAFF overexpression in humanized BAFF-transgenic mice drives a S100a6+ mature B-cell subset that triggers endothelial apoptosis and pulmonary vascular remodeling.
- Why it matters: The mechanisms linking SLE autoimmune dysregulation to fatal PAH progression are poorly defined, limiting effective therapies for SLE-PAH.
- What they did: The study measured BAFF in SLE-PAH patients and animal models, then used single-cell RNA sequencing, flow cytometry, histology, and cell-based assays in humanized BAFF-transgenic mice; Belimumab was tested in two SLE-PAH animal models.
- The result: Belimumab neutralization ameliorated autoimmune and cardiopulmonary manifestations and improved survival in both animal models, supporting BAFF inhibition as a therapeutic strategy for SLE-PAH.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.